SCHEMBL365280

SCHEMBL365280

O=C(O)c1cc(Cl)cc(Cl)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX15 P16050 2/20 0.48
TSHR P16473 2/20 0.48
HIF1A Q16665 1/20 0.48
GPR35 Q9HC97 1/20 0.47
TPMT P51580 1/20 0.44
KMO O15229 4/20 0.43
MCL1 Q07820 1/20 0.40
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 1/20 0.39
ACMSD Q8TDX5 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
S1PR2 O95136 1/20 0.39
HCAR1 Q9BXC0 1/20 0.39
HCAR2 Q8TDS4 2/20 0.38
AKR1C4 P17516 1/20 0.38
AKR1C3 P42330 1/20 0.38
AKR1C2 P52895 1/20 0.38
AKR1C1 Q04828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29462184 1.00 ALOX15 (0.48) ALOX15TSHRHIF1AGPR35TPMT
Hydrochloric Acid SCHEMBL7233021 0.98 ALOX15 (0.46) ALOX15TSHRHIF1AGPR35TPMT
SCHEMBL744473 0.88 ALOX15 (0.61) ALOX15TSHRHIF1AGPR35TPMT
Hydrochloric Acid SCHEMBL28932404 0.86 ALOX15 (0.58) ALOX15TSHRHIF1AGPR35TPMT
SCHEMBL7233011 0.82 S1PR2 (0.39) TSHRGPR35TPMTKMOALDH1A1
SCHEMBL30097621 0.80 LMNA (0.59) S1PR2
SCHEMBL21199852 0.80 TSHR (0.71) ALOX15TSHRHIF1AGPR35TPMT
SCHEMBL9772756 0.80 MAPT (0.41) GPR35TPMTALDH1A1MAPK1SMN1; SMN2
SCHEMBL11616643 0.80 LMNA (0.59) S1PR2
SCHEMBL20011025 0.79 GPR35 (0.42) ALOX15TSHRHIF1AGPR35TPMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12581252-B2 Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors RELAY THERAPEUTICS, INC. (US) 2026-03-17 US disclosed
US-12514858-B2 CD38 inhibitors Astellas Engineered Small Molecules US, Incorporated (US) 2026-01-06 US disclosed
EP-4561562-A2 TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF Ensem Therapeutics, Inc. (US) 2025-06-04 EP disclosed
US-20250171444-A1 PI3Ka INHIBITORS PIKAVATION THERAPEUTICS, INC. 2025-05-29 US disclosed
US-20250092033-A1 HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Beijing Avistone Biotechnology Co., Ltd. (CN) 2025-03-20 US disclosed
US-12219327-B2 Substituted isoindolines as PI3K-alpha inhibitors RELAY THERAPEUTICS, INC. (US) 2025-02-04 US disclosed
EP-4458818-A1 HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF Beijing Avistone Biotechnology Co., Ltd. (CN) 2024-11-06 EP disclosed
US-20240287058-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2024-08-29 US disclosed
WO-2024026128-A2 TRICYCLIC ARYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2024-02-01 WO disclosed
US-20230353959-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-11-02 US disclosed
US-6200933-B1 LOW TOXICITY TO HUMANS AND CATTLE KUREHA KAGAKU KABUSHIKI KAISHA (JP) 2001-03-13 US disclosed
EP-1069112-A1 N-(PHENYLSULFONYL) PICOLINAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND HERBICIDE KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2001-01-17 EP disclosed
US-6159901-A 6-phenoxy picolinic acid alkylidene hydrazide derivative, process for producing the same and herbicide using the same KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2000-12-12 US disclosed
EP-1020444-A1 6-PHENOXYPICOLINIC ACID, ALKYLIDENEHYDRAZIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND HERBICIDE KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 2000-07-19 EP disclosed
EP-0949248-A1 6-(NONSUBSTITUTED OR SUBSTITUTED) PHENOXYPICOLINIC ACIDS, PROCESS OF PREPARING THE SAME, AND AGRICULTURAL/HORTICULTURAL GERMICIDES CONTAINING THE SAME KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1999-10-13 EP disclosed
EP-0882715-A1 NOVEL N-(UNSUBSTITUTED OR SUBSTITUTED)-4-SUBSTITUTED-6-(UNSUBSTITUTED OR SUBSTITUTED)PHENOXY-2-PYRIDINECARBOXAMIDES OR THIOCARBOXAMIDES, PROCESSES FOR PRODUCING THE SAME, AND HERBICIDES KUREHA KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1998-12-09 EP disclosed
US-4764522-A ANTIDEPRESSANT, ANTIPARKINSON DISEASE HOFFMANN-LA ROCHE INC. (US) 1988-08-16 US disclosed
US-4104274-A 1-Substituted-2-(2-pyridinyl)ethanone N-oxides WARNER-LAMBERT COMPANY (US) 1978-08-01 US disclosed
US-4076720-A 1-Substituted-2-(2-pyridinyl)ethanone N-oxides WARNER-LAMBERT COMPANY (US) 1978-02-28 US disclosed
US-4056619-A 1-Substituted-2-(2-pyridinyl)ethanone N-oxides WARNER-LAMBERT COMPANY (US) 1977-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250092033-A1 HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF CYP19A1, WEE1, WEE2 ALOX15 128/4885TSHR 4055/4885HIF1A 349/4885
US-12219327-B2 Substituted isoindolines as PI3K-alpha inhibitors PIK3CD, PIK3CB, PIK3R1 ALOX15 4083/4885TSHR 4529/4885HIF1A 2187/4885
US-20240287058-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF PIK3CA, PIK3CB, PIK3CD ALOX15 3342/4885TSHR 4478/4885HIF1A 1991/4885
US-20250171444-A1 PI3Ka INHIBITORS PIK3CA, PIK3C2A, PIK3R5 ALOX15 4233/4885TSHR 2472/4885HIF1A 723/4885
US-12581252-B2 Substituted pyrrolo[3,4-b]pyridines as PI3K-α inhibitors RORB, ROR1, RORA ALOX15 3499/4885TSHR 146/4885HIF1A 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.